Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001964306-25-000070
Filing Date
2025-02-18
Accepted
2025-02-18 17:27:44
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3572
  Complete submission text file 0001964306-25-000070.txt   5026
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Subject) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-38693 | Film No.: 25636232
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O ALLOGENE THERAPEUTICS, INC. 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address
MESSEMER DEBORAH M. (Reporting) CIK: 0001754424 (see all company filings)

Type: 144